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Abstract
Background: In Uganda, isoniazid plus ethambutol is used for 6 months (6HE) during the continuation treatment phase of
new tuberculosis (TB) cases. However, the World Health Organization (WHO) recommends using isoniazid plus rifampicin for
4 months (4HR) instead of 6HE. We compared the impact of a continuation phase using 6HE or 4HR on total cost and
expected mortality from the perspective of the Ugandan national health system.
Methodology/Principal Findings: Treatment costs and outcomes were determined by decision analysis. Median daily drug
price was US$0.115 for HR and US$0.069 for HE. TB treatment failure or relapse and mortality rates associated with 6HE vs.
4HR were obtained from randomized trials and systematic reviews for HIV-negative (46% of TB cases; failure/relapse –6HE:
10.4% vs. 4HR: 5.2%; mortality –6HE: 5.6% vs. 4HR: 3.5%) and HIV-positive patients (54% of TB cases; failure or relapse –6HE:
13.7% vs. 4HR: 12.4%; mortality –6HE: 16.6% vs. 4HR: 10.5%). When the initial treatment is not successful, retreatment
involves an additional 8-month drug-regimen at a cost of $110.70. The model predicted a mortality rate of 13.3% for
patients treated with 6HE and 8.8% for 4HR; average treatment cost per patient was predicted at $26.07 for 6HE and $23.64
for 4HR. These results were robust to the inclusion of MDR-TB as an additional outcome after treatment failure or relapse.
Conclusions/Significance: Combination therapy with 4HR in the continuation phase dominates 6HE as it is associated with
both lower expected costs and lower expected mortality. These data support the WHO recommendation to transition to a
continuation phase comprising 4HR.
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Introduction
The public health burden of tuberculosis (TB) disproportion-
ately affects developing countries. Limited resources in these
countries increase the risk of suboptimal treatment and necessitate
financial analyses that inform health policy decisions. HIV
increases the risk for primary active disease and reactivation TB,
and has compounded the TB epidemic in sub-Saharan Africa
which bears 80% of the HIV-TB co-infected patient burden [1].
Curative TB treatment requires a prolonged course of a
combination of antibiotics that is divided into a 4-drug, 2-month
intensive phase of rifampicin, isoniazid, pyrazinamide and
ethambutol (2RHZE), followed by a continuation phase of 2
drugs administered for 4–6 months depending on the choice of
regimen [2]. Directly observed therapy, short course (DOTS),
introduced in 1994, emphasized governmental commitment and
ownership of TB control programs, TB case detection, standard-
ized short-course chemotherapy, regular drug supply and imple-
mentation of monitoring systems [3]. Initially, six months of
isoniazid plus thiacetazone (6HA) was recommended by the World
Health Organization (WHO) for the continuation phase rather
than a rifampicin-containing regimen. This was to preserve
sensitivity to rifampicin for retreatment. Due to severe skin
reactions observed in HIV-positive individuals [4], the WHO
recommended that national TB programs change the continuation
phase to 6 months of isoniazid plus ethambutol (6HE) in 1991 [5].
In 2003, as evidence mounted in support of rifampicin throughout
TB treatment, the WHO recommended one of two approaches for
the continuation phase of TB treatment; 6 months of isoniazid plus
ethambutol (6HE) or 4 months of isoniazid plus rifampicin (4HR)
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DOT [6]. As a result of clinical trial evidence of the superiority of
4HR over 6HE in the continuation phase with significantly lower
relapse rates (5% compared to 10%) [7], the WHO recommended
that TB programs transition to a continuation phase of 4HR. In
2008, 23 countries including 4 high burden countries (13% of the
global TB burden) were still using only 2 months of rifampicin. In
2009, the WHO released preliminary guidelines that reinforced
this position and, in 2010, final guidance recommending the
phase-out of 6HE in the continuation phase was published [8]. In
the 2011 WHO Global TB report, 3 high-burden countries still
reported using rifampicin for only 2 months (Nigeria, Afghanistan,
Pakistan) [1]. Although Uganda is listed as using rifampicin
throughout treatment, this option is made available only to
children in its national guidelines [9].
Comparative effectiveness and cost analyses of alternative
treatment strategies using 6HE versus 4HR inform health policy
decisions for TB programs in resource-poor settings such as
Uganda. Therefore, we sought to model the impact of the use of
4HR in the continuation phase of TB treatment compared to the
use of 6EH on expected patient mortality and costs with and
without inclusion of the risk estimates for multi-drug resistance. To
that end, we developed two decision analytic models to evaluate
healthcare-related costs in a hypothetical cohort of Ugandan TB
patients initiated on either a continuation phase of 6HE or the
alternative regimen of 4HR.
Methods
All analyses were conducted from the perspective of the
Ugandan national health care system. In our first model (Model
#1, see Figure 1), all patients were considered to be TB treatment
naı ¨ve and eligible for treatment as new TB cases. In summary,
patients received treatment consisting of the fixed-dose regimen
Figure 1. Model #1.
doi:10.1371/journal.pone.0039187.g001
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assigned to 6HE or 4HR at the decision node. We subdivided our
model into an HIV-positive and an HIV-negative arm to account
for the high prevalence of HIV in TB patients in Uganda (54%)
[10]. For HIV-negative patients, the likelihood of a favorable
treatment outcome was based on evidence from two randomized
clinical trials between the two treatment strategies that were
conducted in mostly HIV-negative populations [7,11]. An
unfavorable treatment outcome was defined as the sum of
treatment failure, relapse, and within trial mortality. For HIV-
positive patients, the likelihood of these three clinical endpoints
was based on a systematic review of randomized, controlled trials
and cohort studies of rifampicin for either 2 or 6 months in HIV-
positive patients with TB. Patients with a favorable treatment
outcome only accrued the cost of TB treatment. Patients with
unfavorable treatment outcomes (relapse, failure) were assumed to
progress to retreatment involving a daily injection of streptomycin
for 2 months and concomitant RHZE followed by 1 month of
RHZE and 5 months of RHE, as per the WHO and national
guidelines [8,12]. The two retreatment outcomes included in the
model were completion of treatment and all-cause mortality,
which was varied for HIV-positive and HIV-negative patients
requiring re-treatment based on data from a prospective Ugandan
cohort [13].
In Model #2, we allowed for the additional option of MDR-TB
treatment. Following unfavorable TB treatment of a new case,
patients could either progress to retreatment or be treated for
multi-drug resistant TB (MDR-TB), based on reported estimates
of the local MDR-TB prevalence for previously treated TB
patients in Uganda [14]. The MDR-TB treatment outcomes
included in the model were either treatment completion or all-
cause mortality. The rate of mortality among HIV-negative as well
as HIV-positive MDR-TB patients was based on data reported by
the Lesotho national MDR-TB program [15].
Based on our models, we estimated the average cost per treated
patient, the expected mortality rate by treatment, as well as the
cost per life saved. Sensitivity analyses were done by varying select
inputs, applying the cost of DOT, varying the rate of MDR-TB in
the 4HR arm and the percentage of patients that are able to access
MDR-TB treatment. We considered a treatment strategy to be
dominant if it was associated with both lower costs as well as lower
mortality. For strategies that were associated with higher costs and
lower mortality we calculated the cost per life saved. All
calculations were performed in Excel 2007 (Microsoft Corpora-
tion, Redmond, WA, USA).
Costs of Treatment of New TB Cases
Drug costs for treatment of new TB cases in our model were
based on published international drug prices (2008), are expressed
in United States dollars ($), and are displayed in Table 1 [16]. The
price of fixed dose combination HE (150 mg/400 mg) ranged
from $0.025–$0.0378 per pill (full range used in sensitivity
analyses) and the median listed price of $0.0346 was used
throughout the analysis. The total daily drug cost was therefore
estimated to be $0.0692, based on daily dosing (2 pills/day). In
comparison, the price of fixed dose combination HR (150 mg/
300 mg) ranged from $0.0390–$0.0814 per pill, with a median
price of $0.0576 and daily drug cost of $0.1152, which were also
based on daily dosing (2 pills/day).
In the continuation phase of the treatment of new TB cases, the
national TB program calls for 6 monthly clinic visits to monitor for
treatment progress and adverse events and for drug refills. The
currently used 6HE regimen involves an additional 2 clinic visits
compared to the 4HR regimen. An internal analysis was
conducted over the course of one week in June 2011 at the
integrated TB/HIV clinic at the Infectious Diseases Institute (IDI)
in Kampala, Uganda [17], which showed that the average follow-
up visit conducted by a nurse in the continuation phase of
Table 1. Treatment of new TB cases.
Treatment of new TB cases 6HE 4HR Difference Source Data
Efficacy
HIV-negative patients
Treatment Success 84.0% 91.3% 7.2% Jindani [7], Nunn [11]
a
Treatment Failure/Relapse 10.4% 5.2% 5.2% Jindani [7], Nunn [11]
a
Treatment Mortality 5.6% 3.5% 2.0% Jindani [7], Nunn [11]
a
HIV-positive patients
Treatment Success 69.7% 77.1% 7.4% Khan [21]
a
Treatment Failure/Relapse 13.7% 12.4% 1.3% Khan [21]
Treatment Mortality 16.6% 10.5% 6.1% Khan [21]
Costs
Daily Drug Costs $0.07 $0.12 $0.05 IDPIG [16]
Days on Drug Therapy 168 112 – MOH [9]
Total Drug Cost for new TB cases $11.63 $12.90 $1.28 IDPIG [16]
b
Cost per Clinic Visit $0.19 $0.19 – IDI
c
Number of Monthly Clinic Visits 6 4 – MOH [9]
aTreatment success was defined as patients who did not experience failure, relapse, or within-trial mortality. For HIV-negative patients, our definition of treatment
success varies slightly from Jindani [7] and Nunn [11] in that we assume that patients with doubtful or doubtfully favorable status are included in the treatment success
category.
bDefined as 6HE: $0.0692 times 168 days = $11.63; 4HR: $0.1152 times 112 days = $12.90.
cInternal analysis conducted at the Infections Diseases Institute in Kampala, Uganda.
doi:10.1371/journal.pone.0039187.t001
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Ugandan health care setting, these patients are routinely seen by a
TB nurse at a salary of approximately 1 million Ugandan Shillings
(UGX) per month (costs obtained internally from the IDI), which
was equivalent to $400 based on the exchange rate when this
analysis was conducted in 2011 (1$=2,500 UGX). This translated
into a cost for a 5-minute visit of 484 UGX, or $0.19.
In Uganda, due to the potential for unfavorable drug-drug
interactions, HIV-TB co-infected patients receiving nevirapine
(NVP) as part of their combination antiretroviral therapy (cART)
regimen are switched to the more expensive efavirenz (EFV) for
the duration of rifampicin treatment [18]. However, information
obtained from a HIV treatment information center in Uganda
(personal communication, S. Zawedde AIDS Treatment Informa-
tion Centre, the IDI, Makerere University, Kampala, Uganda)
and data from our clinic (unpublished) suggest that these patients
are rarely switched back to NVP after completing rifampicin
treatment. Since patients receiving 6HE remain on EFV-based
regimens, we assumed no incremental cART related costs in our
4HR cohort. Lastly, even though directly observed treatment
Table 2. TB Retreatment and MDR-TB Treatment.
TB Retreatment Efficacy Basecase Source Data
% of patients accessing retreatment 100.0% Assumption
a
HIV-negative patients
Treatment Success 93.2% Jones-Lopez [13]
b
Treatment Mortality 6.8% Jones-Lopez [13]
HIV-positive patients
Treatment Success 80.0% Jones-Lopez [13]
b
Treatment Mortality 20.0% Jones-Lopez [13]
TB Retreatment Costs
Sputum Culture $48.00 Makerere University
c
Streptomycin (56 vials) $5.64 NTLP
d
Streptomycin administration (56 injections) $23.80 IDI
e
6 Clinic Visits $1.14 MOH [9]
RHZE
f, if patient ,50 kg, 40% of sample (84 days) $14.04 NTLP
d
RHZE, if patient .50 kg, 60% of sample (84 days) $18.72 NTLP
d
RHE
g $15.27 NTLP
d
Sum $110.70
Treatment Costs of Non-surviving Patients 50.0% Jones-Lopez [13]
h
MDR-TB Treatment
MDR-TB Treatment Efficacy
% of patients accessing retreatment 100.0% Assumption
a
MDR-TB Prevalence 11.7% Lukoye [14]
HIV-negative patients
Treatment Success 80.0% Seung [15]
b
Treatment Mortality 20.0% Seung [15]
HIV-positive patients
Treatment Success 67.9% Seung [15]
b
Treatment Mortality 32.1% Seung [15]
MDR-TB Treatment Costs
MDR-TB Treatment Costs $3,355.00 Tupasi [25]
MDR-TB Treatment Costs of Non-surviving Patients 26.2% Seung [15]
i
aThe actual proportion of patients that are able to access either re-treatment or MDR-TB treatment is not reported for Uganda. However, we based our model on
optimal access to care and varied this parameter in sensitivity analyses.
bThe measures of treatment success in our analysis is different from the original publications by Jones-Lopez [13] and Seung [15]. We simplistically assumed that all
surviving patients experienced a successful treatment outcome in our model and applied the full cost of TB re-treatment or MDR-TB treatment to surviving patients.
cDepartment of Medical Microbiology, Makerere University Kampala, Uganda.
dUgandan National Tuberculosis and Leprosy Program (NTLP) reported in 2010.
eInternal analysis conducted at the Infections Diseases Institute in Kampala, Uganda.
fRHZE, rifampicin, isoniazid, pyrazinamide, ethambutol.
gRHE, rifampicin, isoniazid, ethambutol.
hFor HIV-positive and HIV-negative patients combined, the mortality rate in Jones-Lopez [13] was reported as 7, 17, and 14 in the periods of 0–2 months, 2–5 months,
and 5–8 months, respectively. Since more detailed information on the timing of deaths was not available, we assumed that these patients would have incurred half of
the relevant treatment costs.
iIn Seung [15], death occurred after a median 66 days in treatment. Among surviving patients, the median duration of treatment was reported at 252 days, thus, we
assumed that non-surviving patients would consume 26.2% (66/252=26.2%) of resources relative to surviving patients.
doi:10.1371/journal.pone.0039187.t002
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doi:10.1371/journal.pone.0039187.g002
Rifampin throughout TB Treatment
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39187(DOT) is currently not the standard of care in Uganda, we also
explored the monthly cost of clinic-based DOT in sensitivity
analyses, based on cost-data reported for Zambia [19].
Retreatment Costs
Retreatment drug costs were based on actual procurement costs
incurred by the National Tuberculosis and Leprosy Program
(NTLP) in Uganda in 2010 (Table 2). The average procurement
cost per vial of streptomycin was reported at $0.10. We also
included the cost of streptomycin administration, assuming a daily
5-minute clinic visit at a cost of $0.19. The cost of a syringe
($0.09), antiseptic iodine solution ($0.02), gauze ($0.09), and
sticking plaster ($0.03), were based on institutional costs from a
previous analysis [20], yielding a total cost per injection of $0.53
As per the national guidelines, samples (sputum, lymph node
aspirates) of patients initiating retreatment are to be sent for
culture and drug and sensitivity testing [12]. As national data on
which proportion of retreatment patients are able to produce
samples was not available, we also assumed that sputum cultures
were obtained from all retreatment patients at a cost of $48 per
culture (Department of Medical Microbiology, Makerere Univer-
sity Kampala, Uganda).
The NTLP lists the price of fixed dose combination RHZE
(150 mg/75 mg/400 mg/275 mg) used in the first 3 months of
retreatment at $0.0557 per pill [16]. However, dosing is weight-
dependent and involves 3 tablets a day in patients weighing less
than 50 kg and 4 tablets a day in patients weighing more than
50 kg [12], from which we generated a daily cost of $0.17 and
Table 3. Results from Sensitivity Analyses.
Cost/Life Saved 4HR vs. 6HE
Sensitivity Analyses Basecase Sensitivity Range Model #1 Model #1 Model #2 Model #2
Treatment Specific Efficacy Difference Low High Low High Low High
HIV-negative patients
Treatment Failure/Relapse
a 5.2% 0.9% 16.0% $4 Dominant Dominant Dominant
Treatment Mortality
a 2.0% 0.6% 10.8% Dominant Dominant Dominant Dominant
HIV-positive patients
Treatment Failure/Relapse
b 1.3% 20.1% 6.0% Dominant Dominant Dominant Dominant
Treatment Mortality
b 6.1% 3.4% 8.6% Dominant Dominant Dominant Dominant
Treatment Specific Costs
Total Drug Cost for new TB cases
c $1.28 2$0.74 $5.89 Dominant $45 Dominant Dominant
Other Efficacy Parameters Basecase Low High Low High Low High
HIV-negative patients
Retreatment Mortality
d 6.8% 3.4% 10.1% Dominant Dominant Dominant Dominant
MDR-TB Treatment Mortality 20.0% 10.0% 30.0% – – Dominant Dominant
HIV-positive patients
Retreatment Mortality
d 20.0% 10.0% 30.0% Dominant Dominant Dominant Dominant
MDR-TB Treatment Mortality 32.1% 16.1% 48.2% – – Dominant Dominant
% of Patients able to access
Retreatment 100.0% 0.0% 50.0% $20 Dominant Dominant Dominant
MDR-TB Treatment 100.0% 0.0% 50.0% – – Dominant Dominant
MDR-TB Prevalence
Among Previously Treated Patients 11.7% 4.8% 22.6% – – Dominant Dominant
Other Cost Parameters Basecase Low High Low High Low High
Cost per Clinic Visit
e $0.19 $0.15 $0.25 Dominant Dominant Dominant Dominant
Retreatment Cost
e $110.70 $83.02 $138.37 Dominant Dominant Dominant Dominant
MDR-TB Treatment Cost
e 3,355.00 2,516.25 4,194.75 – – Dominant Dominant
DOT, Monthly Cost
f $0.00 $7.83 $16.32 Dominant Dominant Dominant Dominant
Treatment Cost of Non-surviving Patients
Treatment of new TB cases
e 50.0% 25.0% 75.0% Dominant Dominant Dominant Dominant
RetreatmentI
e 50.0% 25.0% 75.0% Dominant Dominant Dominant Dominant
MDR-TB 26.2% 15.0% 40.0% – – Dominant Dominant
aBased on average upper and lower 95% CI of the center adjusted odds ratio of unfavorable status of 6HE vs. 4HR from Jindani [7] and Nunn [11].
bBased on 95% confidence interval from Khan [21].
cBased on the highest and lowest quoted price from IDPIG [16].
dAssuming a 50% variation around the mortality estimate.
eAssuming a 25% variation around this cost estimate.
fBased on confidence interval reported in Aspler [19].
doi:10.1371/journal.pone.0039187.t003
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therapy at the IDI in 2009 suggested that the proportion of
baseline weights below and above 50 kg was 40% and 60%,
respectively, which is the ratio we used to generate the weight-
adjusted cost of RHZE in our model. In the remaining 5 months
of retreatment treatment, fixed dose combination RHE (150 mg/
75 mg/275 mg) was listed at $0.0364 per pill and involved 3
tablets a day, resulting in a daily drug cost of $0.1091 (NTLP). For
the proportion of patients with a mortality outcome in our model,
50% of the retreatment drug costs were applied.
Treatment Efficacy
Treatment efficacy was stratified by HIV-status. In mostly HIV-
negative patients, the clinical efficacy of 6HE versus 4HR in the
continuation phase of treatment for new TB cases has been
evaluated in two prospective, randomized clinical trials [7,11]. In
these two studies combined, a total of 627 patients in the two 6HE
arms and 629 patients in the two 4HR arms were clinically
evaluable at the end of follow-up. The total number of deaths
during the assessment period was 37 (6HE) and 23 (4HR). Using
the sum of clinically evaluable patients and deaths in the
denominator, treatment failure and relapse were 69 (10.4%) in
the two 6HE arms and 34 (5.2%) in the two 4HR arms,
respectively. This difference was statistically significant in both
trials individually (P=0.006 and P=0.002, respectively). In
sensitivity analyses, we used the average of the two 95%
confidence intervals around these estimates.
Efficacy estimates in HIV-positive patients, were based on a
systematic review of treatment outcomes among HIV-infected
patients with TB [21]. We used the pooled event rate of short-term
(2 months) rifampicin treatment as a proxy to inform modeled
outcomes in the 6HE arm of our model and the longer-term (6
months) rifampicin treatment as a proxy for our 4HR arm. The
sum of the pooled failure and relapse event rates were used to
define unfavorable treatment outcomes, which added up to 13.7%
in the 6HE arm and 12.4% in the 4HR arm of our model; the
Figure 3. Sensitivity Analysis. (a) Per patient savings by MDR-TB prevalence and 20%–100% access to MDR-TB treatment. (b) Cost/life saved by
MDR-TB prevalence and 20%–100% access to MDR-TB treatment.
doi:10.1371/journal.pone.0039187.g003
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respectively. The 95% confidence intervals around the pooled
event rates served as inputs in sensitivity analyses. The final
efficacy parameter we included was the mortality rate of patients
on the retreatment regimen, which ranged from 6.8% in HIV-
negative patients to 20.0% in HIV-positive patients [13] and this
was varied by 2/+50% in sensitivity analyses.
Multi-Drug Resistant TB (MDR-TB)
In model #2, we evaluated the impact of MDR-TB. The
prevalence of MDR-TB in Uganda is currently estimated at in
11.7% in patients previously treated for TB [22]. MDR-TB
treatment involves a combination of 4 active drugs from the
following: first-line drugs to which the TB strain remains
susceptible, injectable aminoglycosides, fluoroquinolones, bacte-
riostatic second-line drugs and other more toxic alternatives [23].
Given the toxicity of the MDR-TB treatment, patients must be
followed closely and have a higher risk of treatment failure [24].
MDR-TB treatment has been associated with average treatment
costs among surviving and non-surviving patients as high as
$3,355 [25].
We assumed that the probability of a favorable outcome
remained unchanged in the 4HR as well as the 6HE treatment
arm compared to model #1. We added a chance node following
an unfavorable treatment outcome for a new TB case, where
11.7% required treatment for MDR-TB (Figure 2). We assumed
that no patients were found to have MDR-TB before starting
treatment for new TB cases and that all patients requiring
treatment for MDR-TB were able to access it. The remaining
88.3% (100%211.7%) were assumed to initiate standard retreat-
ment treatment. Among treated patients, MDR-TB related
mortality was reported at 32.1% in patients co-infected with
HIV and 20.0% in HIV-negative patients [15]. We varied this
mortality rate by 2/+50% in the sensitivity analyses.
To account for the possibility that the rate of MDR-TB may
increase if 4HR were to replace 6HE, we ran additional sensitivity
analyses where we varied the rate of MDR-TB among previously
treated patients in the 4HR treatment arm only. We assumed that
the rate of MDR-TB among patients in the 6HE treatment arm
would remain unchanged at 11.7% [13]. In this calculation, we
also varied the percentage of patients that were assumed to be able
to access MDR-TB treatment in Uganda from 20%–100%;
patients who were assumed not to be able to access MDR-TB
treatment did not incur any cost and had a mortality outcome in
the model. For increasing rates of MDR-TB, we evaluated the
average savings per patient associated with 4HR as well as the cost
per life saved in cases where 4HR was the more expensive option.
Results
Model #1
Model #1 structure and results are displayed in Figure 1. The
average total cost of treatment of a new TB case, including drug
costs and clinic visits, was $12.77 for 6HE and $13.66 for 4HR.
The average total cost of a completed course of retreatment
regimen, including the cost of drugs, streptomycin administration,
clinic visits and TB sputum culture, and adjusted for baseline
weight was $110.70. Hence, the expected average cost of TB
treatment in the continuation phase was $26.07 for 6HE, which
compared to $23.64 for 4HR. The expected cost savings
associated with 4HR were $2.42 per patient. Furthermore, our
model predicted an expected mortality rate of 13.3% associated
with 6HE treatment and 8.8% associated with 4HR treatment.
Therefore, we did not calculate an incremental cost-effectiveness
ratio, since 4HR was associated with both lower cost as well as
lower expected mortality in the base case (e.g. dominant strategy).
Model #2
Model #2 structure and results are displayed in Figure 2.
Including treatment for MDR-TB as an additional outcome for
previously treated patients with unfavorable outcomes increased
the average cost to $65.86 for 6HE and to $53.12 for 4HR. The
cost difference between the 6HE and 4HR treatment options
increased to $12.74 per patient. The expected mortality increased
slightly to 13.5% and 8.9%, respectively, and 4HR continued to
be the dominant treatment strategy (e.g. lower cost and lower
mortality) relative to 6HE.
Sensitivity Analyses
Results from our one-way sensitivity analyses are displayed in
Table 3. We found that 4HR generally dominated 6HE over a
wide range of inputs in both models. In the three cases where 4HR
did not dominate 6HE, it was associated with cost-effectiveness
thresholds ranging from $4–$45 per life saved. We also found that
a higher rate of MDR-TB in the 4HR arm of our model
diminished the average cost-savings per patient. Depending on the
proportion of patients that were assumed to be able to access
MDR-TB treatment, 4HR was associated with zero cost-savings
relative to 6HE if the MDR-TB prevalence increased from 11.7%
to 17%–22% (see Figure 3a). At higher rates, 4HR was expected to
increase the average treatment cost, but was associated with a cost
per life saved of $80–$674 even at resistance rates as high as 30%
(see Figure 3b).
Discussion
In our 2 models comparing 4HR to 6HE, 4HR is associated
with a lower expected mortality rate as well as lower total cost.
The first model does not consider the cost of MDR-TB cases, but
rather just the cost of the TB treatment regimens in new patients
and in those requiring retreatment. In estimates from the WHO, a
decreased cost of $4–10 was estimated [8]. Our estimate of $2.42
per patient falls slightly below this range. More importantly,
because the rate of relapse or failure is higher in patients who take
6HE based on data from clinical trials, this increased likelihood of
an unfavorable outcome may lead to an increased risk of MDR-
TB. When we considered the cost of MDR-TB in our second
model, the cost difference was even larger ($12.74 per patient).
Thus, using the WHO estimate of 40,000 new TB cases annually
in Uganda, our model results suggest that adopting 4HR may
reduce the annual TB-related mortality burden by ,1,800
patients and may lead to expected savings of approximately
$100,000–$500,000 per year to the Ugandan national health care
system.
Our estimate of the number of cases generated is conservative
because we do not model the cost of the patients who also have
isoniazid mono-resistance and who are often cured with 4HR in
the continuation phase, but have an increased rate of treatment
failure with 6HE [26]. Furthermore, we do not consider additional
4HR-related benefits; TB treatment completion rates in the
regimen that is 2 months shorter will likely be higher. Also, if the
Ugandan TB treatment guidelines for DOT are fully implement-
ed, the results from our sensitivity analysis suggest that the shorter
duration of therapy with 4HR would be expected to result in even
greater cost-savings relative to 6HE.
Our results are largely driven by the lower mortality rate as well
as the lower failure or relapse rate associated with 4HR. In our
model, MDR-TB can only occur in previously treated patients in
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TB rate among previously treated patients were to increase with
4HR (although data from one systematic review suggests higher
TB drug resistance rates with 6HE [26]), total treatment costs
would still be lower with 4HR if the MDR-TB rate were to double
because significantly fewer patients would require re-treatment
due to the lower relapse rates with this shorter regimen.
Furthermore, if the rate of MDR-TB were to increase as high as
30%, 4HR would still be associated with a lower expected
mortality rate at an acceptable cost per life saved of $80–$674
depending on the proportion of patients with access to treatment;
the mortality rate associated with 4HR for new TB cases is
reduced by 2% in HIV-negative patients and 6.1% in HIV-
positive patients. Since this reduction applies to all patients that
enter the model, it has a disproportionately larger impact on
expected mortality than the rate of MDR-TB, which only applies
to the subset of patients that require re-treatment.
One of the limitations of our study is that our cost estimates are
from the perspective of the Ugandan national health care system
with the cost of clinic procedures and cultures based on local rates
and a rate of HIV co-infection of 54%. Similar analyses in other
countries still using the 6HE regimen should be conducted to
understand the generalizability of our results. In addition, our
analysis was based on clinical efficacy results as obtained in several
randomized controlled clinical trials and cohort studies and actual
effectiveness in a real world setting with arguably lower
compliance rates could be different. Other limitations include: 1)
that the majority of the aforementioned studies were not
conducted in Uganda and that these studies did not evaluate
whether the numerical differences in mortality between 4HR and
6HE were statistically significant, 2) we did not evaluate the impact
of increasing rates of MDR-TB in newly treated patients. Lastly,
Green Light Committee (GLC) MDR treatment regimens may
allow for significantly lower costs associated with MDR treatment.
Although MDR-TB treatment is approved by the GLC for
Uganda, drugs are still not available and no patients are currently
on treatment through the national program. Finally, despite
increased emphasis on cost effectiveness to inform health policy
decision-making and coverage decisions, cost effectiveness should
supplement, not replace clinical effectiveness evaluations.
In summary, a transition to the strongly recommended
continuation phase 4HR regimen is associated with lower costs,
lower mortality, a lower overall risk for relapse and, therefore, a
reduced need for retreatment. The Ugandan national program
will need to continue to enhance health systems to allow for better
monitoring of drug compliance to implement rifampicin through-
out the course of TB treatment, but the benefit of fewer cases of
retreatment and drug resistant TB as well as cost savings, provide
compelling arguments for change.
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